Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $2.00 → $5.00 | Buy | HC Wainwright & Co. |
Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today - May 14, 2025, at 11:00 AM ESTCRANBURY, N.J., May 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2025. "We had a strong quarter operationally, with significant progress across both our obesity and ocular pipelines," said Carl Spana, Ph.D., Pre
Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory pathways, suppress angiogenesis, and preserve retinal structure and functionTopical and systemic administration options enable potential for earlier intervention than current therapiesResults support the continued development of PL9654 and PL9655 for the treatment of diabetic retinopathy (DR)CRANBURY, N.J., May 9, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new
Company Transitioned onto the OTC Pink CRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the "Series F Warrants"), Series G warrants to purchase up to 7,324,119 shares of common stock (the "Series G Warrants"), and Seri